DSpace Repository

Endothelin-1 as a biomarker of endothelial dysfunction in patients with ankylosing spondylitis after COVID-19

Show simple item record

dc.contributor.author Rakhimova M.B., Akhmedov K.S.
dc.date.accessioned 2023-11-26T15:51:14Z
dc.date.available 2023-11-26T15:51:14Z
dc.date.issued 2023
dc.identifier.citation Тошкент en_US
dc.identifier.issn 2181-7812
dc.identifier.uri http://repository.tma.uz/xmlui/handle/1/9421
dc.description.abstract Currently, there is no doubt about the importance of the role of impaired endothelial functional state in the development of vascular pathology in a number of diseases, including rheumatic. With the advent and large-scale spread of a new coronavirus infection (COVID-19), a high rate of patient’s hospitalizations with ankylosing spondyloarthritis (AS) and the development of extrapulmonary complications, such as myocardial injuries, kidney damage and vascular thromboembolism, were noted. The development of this phenomenon confirms the connection with pronounced endothelial dysfunction and its damage. This article presents the results of evaluation of endothelial dysfunction in AS patients undergoing COVID-19. en_US
dc.language.iso en en_US
dc.relation.ispartofseries УДК;
dc.subject ankylosing spondylitis, COVID-19, endothelial dysfunction. en_US
dc.title Endothelin-1 as a biomarker of endothelial dysfunction in patients with ankylosing spondylitis after COVID-19 en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account